327 related articles for article (PubMed ID: 27706215)
1. Alterations of Myelin Content in Parkinson's Disease: A Cross-Sectional Neuroimaging Study.
Dean DC; Sojkova J; Hurley S; Kecskemeti S; Okonkwo O; Bendlin BB; Theisen F; Johnson SC; Alexander AL; Gallagher CL
PLoS One; 2016; 11(10):e0163774. PubMed ID: 27706215
[TBL] [Abstract][Full Text] [Related]
2. Levodopa responsiveness in Parkinson's disease patients and white matter alterations in diffusion tensor imaging: a cross-sectional tract-based spatial statistics study.
Zhou W; Jiang J; Peng W; Zhou X; Du J; Mo L; Tan C; Liu X; Chen L
Neuroreport; 2021 May; 32(7):636-642. PubMed ID: 33850092
[TBL] [Abstract][Full Text] [Related]
3. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S;
J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Susceptibility Mapping in Parkinson's Disease.
Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
[TBL] [Abstract][Full Text] [Related]
5. Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson's Disease.
Mueller K; Jech R; Ballarini T; Holiga Š; Růžička F; Piecha FA; Möller HE; Vymazal J; Růžička E; Schroeter ML
Cerebellum; 2019 Apr; 18(2):212-224. PubMed ID: 30298443
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal changes of cortical microstructure in Parkinson's disease assessed with T1 relaxometry.
Nürnberger L; Gracien RM; Hok P; Hof SM; Rüb U; Steinmetz H; Hilker R; Klein JC; Deichmann R; Baudrexel S
Neuroimage Clin; 2017; 13():405-414. PubMed ID: 28116233
[TBL] [Abstract][Full Text] [Related]
8. R2* relaxometry analysis for mapping of white matter alteration in Parkinson's disease with mild cognitive impairment.
Kan H; Uchida Y; Ueki Y; Arai N; Tsubokura S; Kunitomo H; Kasai H; Aoyama K; Matsukawa N; Shibamoto Y
Neuroimage Clin; 2022; 33():102938. PubMed ID: 34998126
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
[TBL] [Abstract][Full Text] [Related]
10. Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.
Kolind S; Seddigh A; Combes A; Russell-Schulz B; Tam R; Yogendrakumar V; Deoni S; Sibtain NA; Traboulsee A; Williams SC; Barker GJ; Brex PA
Neuroimage Clin; 2015; 9():574-80. PubMed ID: 26594633
[TBL] [Abstract][Full Text] [Related]
11. Loss of integrity and atrophy in cingulate structural covariance networks in Parkinson's disease.
de Schipper LJ; van der Grond J; Marinus J; Henselmans JML; van Hilten JJ
Neuroimage Clin; 2017; 15():587-593. PubMed ID: 28652971
[TBL] [Abstract][Full Text] [Related]
12. Levodopa and the progression of Parkinson's disease.
Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
[TBL] [Abstract][Full Text] [Related]
13. Regional gray matter changes and age predict individual treatment response in Parkinson's disease.
Ballarini T; Mueller K; Albrecht F; Růžička F; Bezdicek O; Růžička E; Roth J; Vymazal J; Jech R; Schroeter ML
Neuroimage Clin; 2019; 21():101636. PubMed ID: 30558868
[TBL] [Abstract][Full Text] [Related]
14. Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology.
Gao Y; Nie K; Huang B; Mei M; Guo M; Xie S; Huang Z; Wang L; Zhao J; Zhang Y; Wang L
Neurosci Lett; 2017 Sep; 658():121-132. PubMed ID: 28823894
[TBL] [Abstract][Full Text] [Related]
15. Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
Du G; Liu T; Lewis MM; Kong L; Wang Y; Connor J; Mailman RB; Huang X
Mov Disord; 2016 Mar; 31(3):317-24. PubMed ID: 26362242
[TBL] [Abstract][Full Text] [Related]
16. A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics.
Yoritaka A; Abe T; Ohtsuka C; Maeda T; Hirayama M; Watanabe H; Saiki H; Oyama G; Fukae J; Shimo Y; Hatano T; Kawajiri S; Okuma Y; Machida Y; Miwa H; Suzuki C; Kazama A; Tomiyama M; Kihara T; Hirasawa M; Shimura H; Hattori N
BMC Neurol; 2016 May; 16():66. PubMed ID: 27176725
[TBL] [Abstract][Full Text] [Related]
17. Cross-sectional and longitudinal associations between total and regional white matter hyperintensity volume and cognitive and motor function in Parkinson's disease.
Pozorski V; Oh JM; Okonkwo O; Krislov S; Barzgari A; Theisen F; Sojkova J; Bendlin BB; Johnson SC; Gallagher CL
Neuroimage Clin; 2019; 23():101870. PubMed ID: 31150958
[TBL] [Abstract][Full Text] [Related]
18. A Multi-sequence MRI Study in Parkinson's Disease: Association Between Rigidity and Myelin.
Cai J; Kim JL; Baumeister TR; Zhu M; Wang Y; Liu A; Lee S; McKeown MJ
J Magn Reson Imaging; 2022 Feb; 55(2):451-462. PubMed ID: 34374158
[TBL] [Abstract][Full Text] [Related]
19. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
Parkinson Study Group
JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
[TBL] [Abstract][Full Text] [Related]
20. White matter myelin profiles linked to clinical subtypes of Parkinson's disease.
Baumeister TR; Kim JL; Zhu M; McKeown MJ
J Magn Reson Imaging; 2019 Jul; 50(1):164-174. PubMed ID: 30444020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
